home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471085.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
3KB
|
47 lines
Document 1085
DOCN M9471085
TI Immunologic correlates in patients (pts) with head and neck cancer
(SCCHN) treated with interferon alpha (IFN): association between natural
killer cell (NK) activity and prolonged survival (Meeting abstract).
DT 9409
AU Vlock D; Andersen J; Whiteside T; Herberman R; Kirkwood J; Adams G;
Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 02115
SO Proc Annu Meet Am Soc Clin Oncol; 13:A900 1994. Unique Identifier :
AIDSLINE ICDB/94600896
AB 71 pts with recurrent or metastatic SCCHN were entered onto a phase II
noncomparative randomized trial of IFN at 2 dosage schedules (EST
P-Z386): low dose IFN, 6 x 10(6) U/m2 daily x 3 every 4 wk or high dose
IFN, 12 x 10(6) U/m2, 3x/wk (Proc ASCO, 10:205). While the overall
response rates were low (3 CRs) disease stabilization was noted,
suggesting an antiproliferative, non-cytotoxic role of IFN in this group
of heavily pre-treated pts. Median survival of pts receiving greater
than or equal to 6 wk of IFN was 10 and 12 mo for low and high dose IFN,
respectively. We sought to determine if any immune parameters were
associated with prolonged survival. Pretreatment levels of NK activity,
CD3, CD4, CD5, CD8, CD16, CD19, CD56, DR and the CD4/CD8 ratio were
evaluated. None of the parameters tested was a significant predictor of
survival when evaluated in all cases entered onto study regardless of
therapy duration. No difference in baseline NK activity was noted
between pts who received less than or greater than or equal to 6 wk of
IFN (p=0.90). Among the 35 pts who received greater than or equal to 6
wk of therapy, high baseline NK activity was a significant predictor of
the duration of survival both in a univariate analysis (p=0.04) and when
proportional hazards regression was adjusted for prior weight loss and
chemotherapy (p=0.005), the two covariates associated with survival in
the primary clinical analysis. Survival of pts with median baseline NK
activity of 192 lytic units was greater than 24 mo (N=7) vs 6-12 mo for
pts with median NK activity of 67 (N=13). Baseline CD4, CD8 and CD4/CD8
ratios and the differences between baseline and measurements after 1 wk
of IFN were not associated with the duration of survival. We conclude
that elevated baseline NK activity is associated with increased survival
in pts receiving IFN for greater than or equal to 6 wk.
DE Analysis of Variance Antigens, CD/BLOOD CD4-CD8 Ratio Comparative
Study Head and Neck Neoplasms/BLOOD/*IMMUNOLOGY/MORTALITY/*THERAPY
Human Interferon-alpha/*TOXICITY/*THERAPEUTIC USE Killer Cells,
Natural/DRUG EFFECTS/*IMMUNOLOGY Survival Analysis Survival Rate
MEETING ABSTRACT CLINICAL TRIAL, PHASE II CLINICAL TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).